Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.

Launched by CENTRE ANTOINE LACASSAGNE · Jan 14, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on studying how certain tumor samples can help researchers understand the effectiveness of new cancer treatments. The researchers will collect tumor samples from patients who have a specific mutation, which is a change in the DNA of the tumor that interests them. These samples will be used to create tiny clusters of cancer cells, known as spheroids. By testing different treatments on these spheroids, they hope to find out which therapies work best for tumors with that specific mutation.

To be eligible for this trial, participants need to be at least 18 years old and have a malignant tumor that is either locally advanced or has spread to other parts of the body. They must also have a scheduled procedure to collect a tumor sample as part of their regular medical care. Participants will need to sign an informed consent form, which means they agree to be part of the study after understanding what it involves. It's important to note that certain patients, such as those with multiple tumors or specific infections, may not be eligible. If you decide to participate, you will help advance research that could lead to better treatments for future cancer patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or older.
• • Patient for whom at least one mutation deemed of interest by the investigator has been identified.
• • Patient with a malignant tumor at a locally advanced or metastatic stage, for whom a tissue tumor sample (via surgery, radiology, or endoscopy) is scheduled as part of their standard care.
• • Tumor volume deemed sufficient by the physician to ensure an adequate amount of material for analysis by the pathologist and the transfer of a part of the tumor sample to the Laboratory of Translational Research in Oncology for the study.
• • INR \< 1.5; Platelets \< 50,000/μL.
• • Patient who has been informed of the study and has signed the informed consent form.
• • Patient affiliated with a social security insurance.
• Exclusion Criteria:
• • Patient with multiple primary malignant tumors.
• • Patient with a known HIV, Hepatitis C, or Hepatitis B infection.
• * Patient on:
• • Clopidogrel (hydrogensulfate) or Prasugrel (hydrochloride) or Ticlopidine (hydrochloride) with no possibility of suspension for 5 days,
• • Low molecular weight heparin with no possibility of dose suspension before the procedure,
• • Fondaparinux with no possibility of suspension,
• • Abciximab with no possibility of suspension for 24 hours and aPTT \< 50s and ACT \< 150s,
• • Eptifibatide or Tirofiban Hydrochloride Monohydrate or Argatroban with no possibility of suspension 4 hours before the procedure,
• • Bivalirudin with no possibility of suspension 2-3 hours if CrCL \>50 mL/min or 3-5 hours if CrCL \<50 mL/min before the procedure,
• • Dabigatran etexilate with no possibility of suspension 2-3 days if CrCL \>50 mL/min or 3-5 days if CrCL \<50 mL/min before the procedure.
• * Patient considered vulnerable; vulnerable persons are defined in articles L1121-5 to L1121-8:
• • Pregnant women, parturients, and breastfeeding mothers,
• • Individuals deprived of their liberty by a judicial or administrative decision, individuals hospitalized without consent under articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of article L. 1121-8, and individuals admitted to a healthcare or social facility for reasons other than research,
• • Adults under legal protection or unable to express their consent.